JP2011527339A5 - - Google Patents

Download PDF

Info

Publication number
JP2011527339A5
JP2011527339A5 JP2011517270A JP2011517270A JP2011527339A5 JP 2011527339 A5 JP2011527339 A5 JP 2011527339A5 JP 2011517270 A JP2011517270 A JP 2011517270A JP 2011517270 A JP2011517270 A JP 2011517270A JP 2011527339 A5 JP2011527339 A5 JP 2011527339A5
Authority
JP
Japan
Prior art keywords
solution according
ophthalmic solution
sodium
item
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011517270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527339A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2009/006683 external-priority patent/WO2010004435A2/en
Publication of JP2011527339A publication Critical patent/JP2011527339A/ja
Publication of JP2011527339A5 publication Critical patent/JP2011527339A5/ja
Pending legal-status Critical Current

Links

JP2011517270A 2008-07-09 2009-07-09 眼障害を処置するためのミコフェノール酸ナトリウムのｐＨ特異的な溶液 Pending JP2011527339A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7941308P 2008-07-09 2008-07-09
US61/079,413 2008-07-09
PCT/IB2009/006683 WO2010004435A2 (en) 2008-07-09 2009-07-09 Formulations for treating eye disorders

Publications (2)

Publication Number Publication Date
JP2011527339A JP2011527339A (ja) 2011-10-27
JP2011527339A5 true JP2011527339A5 (enExample) 2012-08-23

Family

ID=41505728

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517270A Pending JP2011527339A (ja) 2008-07-09 2009-07-09 眼障害を処置するためのミコフェノール酸ナトリウムのｐＨ特異的な溶液

Country Status (6)

Country Link
US (1) US20100010082A1 (enExample)
EP (1) EP2310008A4 (enExample)
JP (1) JP2011527339A (enExample)
CN (1) CN102099029A (enExample)
CA (1) CA2729834A1 (enExample)
WO (1) WO2010004435A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108165548B (zh) 2008-09-22 2022-10-14 菲奥医药公司 减小大小的自递送RNAi化合物
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
BRPI1015356A2 (pt) * 2009-06-30 2016-05-10 Allergan Inc composições farmacêuticas oftalmológicas líquidas contendo derivados do ácido propiônico como conservante.
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
US8829053B2 (en) * 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
SG11201507316UA (en) * 2013-03-14 2015-10-29 Panoptica Inc Ocular formulations for drug-delivery to the posterior segment of the eye
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
EP3137118A4 (en) 2014-05-01 2017-11-22 RXi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
KR102256185B1 (ko) 2014-09-09 2021-05-26 아르투로 솔리스 헤레라 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법
US9789080B2 (en) * 2015-09-04 2017-10-17 Insite Vision Incorporated Ophthalmic formulations of mycophenolic acid
US20230158045A1 (en) * 2017-09-25 2023-05-25 Surface Ophthalmics, Inc. Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
EP3691654A4 (en) 2017-09-25 2021-11-24 Surface Pharmaceuticals, Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES
US20210177751A1 (en) * 2017-12-08 2021-06-17 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CA3124945A1 (en) * 2018-12-27 2020-07-02 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US20230144779A1 (en) * 2019-12-20 2023-05-11 Vyome Therapeutics Inc. Formulations and method for treatment of inflammatory diseases
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
WO2022240598A1 (en) 2021-05-10 2022-11-17 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
CN113519461A (zh) * 2021-07-06 2021-10-22 江西中洪博元生物技术有限公司 伴刀豆球蛋白a诱导的小鼠干眼症模型的构建方法及应用
CN114028334B (zh) * 2021-12-10 2023-08-29 卓和药业集团股份有限公司 一种肺部给药的免疫抑制剂的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US4686234A (en) * 1985-11-27 1987-08-11 Syntex (U.S.A) Inc. Mycophenolic acid derivatives in the treatment of inflammatory diseases, in particular rheumatoid arthritis
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
ATE109970T1 (de) * 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ES2248793T3 (es) * 1993-10-01 2006-03-16 Roche Palo Alto Llc Suspensiones orales de alta dosis de mofetil micofenolato.
JPH0930966A (ja) * 1995-07-24 1997-02-04 Gakuzo Tamura 眼科用新規製剤
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US8372814B2 (en) * 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
CN101052631A (zh) * 2004-07-20 2007-10-10 特瓦药厂私人有限公司 结晶霉酚酸钠

Similar Documents

Publication Publication Date Title
JP2011527339A5 (enExample)
JP2018030871A (ja) 非刺激性の眼科用ポビドンヨード組成物
JP2011516537A (ja) 安定性のある眼科用の製剤
CN1292752C (zh) 含依匹那丁的溶液
JP2010536797A5 (enExample)
JP2019517580A (ja) 副交感神経薬および抗交感神経薬でのドライアイ疾患の処置
AU2011274245B2 (en) Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
JP2014533275A5 (enExample)
US20190008832A1 (en) Compositions for the treatment of presbyopia
JP2015110672A (ja) ビマトプロストおよびブリモニジンの固定用量の組み合わせ
CN106455567A (zh) 用于治疗青光眼的组合物和方法
CN110996954A (zh) 低剂量的溴莫尼定组合及其用途
Lee et al. Emerging drugs for ocular hypertension
US10058560B2 (en) Preservative free bimatoprost and timolol solutions
WO2015041294A1 (ja) ポリエチレングリコール含有組成物
WO2013115844A1 (en) Compositions and methods for treatment of glaucoma
WO2003035109A1 (en) Remedies for pruritus
JP2016506931A5 (enExample)
JP2017534658A (ja) プロスタグランジンと一酸化窒素供与体との組み合わせ
JP2016210780A (ja) アゾール系抗真菌薬の眼瞼皮膚への投与
CN108348516B (zh) 外用剂
US10905695B2 (en) Ophthalmic composition for lowering intraocular pressure
JP2003201250A (ja) 掻痒治療剤
US20180221417A1 (en) Treatment of dry eye using amnion released factors
US20250114375A1 (en) Pharmaceutical composition of lifitegrast and loteprednol etabonate